Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

Objective: Breast cancer remains to be the globally leading female cancer. About 15% to 20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive tumors – a more aggressive breast cancer subtype with shortened survival. In the light of new and updated trial data on trastuzu...

Descripción completa

Detalles Bibliográficos
Autores principales: Genuino, Anne Julienne, Chaikledkaew, Usa, The, Due Ong, Reungwetwattana, Thanyanan, Thakkinstian, Ammarin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816496/
https://www.ncbi.nlm.nih.gov/pubmed/31287333
http://dx.doi.org/10.1080/17512433.2019.1637252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816496/
https://www.ncbi.nlm.nih.gov/pubmed/31287333
http://dx.doi.org/10.1080/17512433.2019.1637252

Ejemplares similares